50 results about "Glomerular diseases" patented technology

A method of treating a glomerular disease selected from the group consisting of mesangial proliferative glomerulonephritis, collapsing glomerulopathy, proliferative lupus nephritis, crescentic glomerulonephritis and membranous nephropathy in a subject comprises administering to the subject an effective amount of a glucosylceramide synthase inhibitor.

Focal and segmental glomerulosclerosis (FSGS) is a kidney disorder of unknown etiology and up to 20% of patients on dialysis have this diagnosis. A large family with hereditary FSGS carries a missense mutation in the TRPC6 gene on chromosome 11q, encoding the ion channel protein Transient Receptor Potential Cation Channel 6. The missense mutation is a P112Q substitution, which occurs in a highly conserved region of the protein, enhances TRPC6-mediated calcium signals in response to agonists such as angiotensin II, and alters the intracellular distribution of TRPC6 protein. Previous work has emphasized the importance of cytoskeletal and structural proteins in proteinuric kidney diseases. Our findings suggest a novel mechanism for glomerular disease pathogenesis.

The invention relates to methods, compositions, and kits for the treatment of proteinuria and / or hypertension (e.g., proteinuria and / or hypertension arising from primary renal disease (e.g., focal segmental glomerulosclerosis, glomerular disease) or secondary to other conditions (e.g., diabetes, diabetic nephropathy, liver disease). Specifically, the invention relates to methods involving combination therapy wherein an indoline (e.g., indapamide) is administered in combination with an anti-aldosterone agent (e.g., spironolactone and / or epleronone).

The invention discloses a sinomenine vesicle and a preparation method thereof, a preparation containing the sinomenine vesicle and a preparation method of the preparation, which belong to the field of medicament preparations. The sinomenine vesicle is prepared from sinomenine, a nonionic surfactant and an additive. The sinomenine vesicle is preferably prepared into external gel. A sinomenine transdermal administration external preparation has a unique advantage to the medicament. Due to the application of a novel vesicle administration system, transdermal absorption of the medicament is improved, and a clinical curative effect is enhanced. The sinomenine vesicle can be used for treating rheumatism, rheumatoid arthritis, a glomerular disease, hyperosteogeny, spondylitis, arrhythmia, systemic lupus erythematosus, a heroin addict withdrawal symptom and the like.

The present invention relates to a preventive or therapeutic agent for a glomerular disease which comprises an anti-thrombocytic agent and an HMG-CoA reductase inhibitor as active ingredients. The above agent is useful for prevention and therapy of various glomerular diseases including chronic glomerular nephritis.

The present invention relates to a preventive or therapeutic agent for a glomerular disease which comprises an anti-thrombocytic agent and an HMG-CoA reductase inhibitor as active ingredients. The above agent is useful for prevention and therapy of various glomerular diseases including chronic glomerular nephritis.

The present invention provides methods of treating Alport syndrome in a subject by the administration of an agent that can blocks the activation of RAC1 / CDC42 members of the rho family of small GTPases. Such agents include, but are not limited to, the endothelin receptor antagonists such as bosentan and letairis and neutralizing antibodies to endothelin-1. Such administration prevents invasion of the glomerular capillary tufts by mesangial lamellipodial / filopodial processes, blocks mesangial process invasion abrogates the deposition of laminin 211 in the GBM, and prevents the activation of maladaptive expression of proteins known to contribute to glomerular disease progression.

It is intended to provide a medicinal composition which is efficacious in preventing or treating a glomerular disease, in particular, a progressive chronic glomerular disease. A preventive / remedy for a glomerular disease containing pyridoxamine or its salt and an angiotensin II receptor antagonist.

The invention provides an establishment method of a glomerular disease classification and typing model based on immunoglobulin quantitative detection and an application thereof in detection and classification and typing of glomerular diseases. The model can classify and classify patients with glomerular diseases so as to support clinical decisions, reduce medical expenditure, reduce infection probability and improve patient acceptability.

Focal and segmental glomerulosclerosis (FSGS) is a kidney disorder of unknown etiology and up to 20% of patients on dialysis have this diagnosis. A large family with hereditary FSGS carries a missense mutation in the TRPC6 gene on chromosome 11q, encoding the ion channel protein Transient Receptor Potential Cation Channel 6. The missense mutation is a P112Q substitution, which occurs in a highly conserved region of the protein, enhances TRPC6-mediated calcium signals in response to agonists such as angiotensin II, and alters the intracellular distribution of TRPC6 protein. Previous work has emphasized the importance of cytoskeletal and structural proteins in proteinuric kidney diseases. Our findings suggest a novel mechanism for glomerular disease pathogenesis.

The invention relates to new medical applications of a natural monomer compound pterostilbene, in particular to applications of the pterostilbene in preparation of medicines for preventing and treating a chronic glomerular disease, and applications of pterostilbene in preparation of medicines for preventing and treating progressive chronic glomerular disease. Animal test results show that the pterostilbene has an obvious effect on prevention and improvement of a glomerular function and an organic injury of a fructose model rat renal. The pterostilbene is matched up with relevant adjuvants, a conventional preparation method can be utilized to obtain a health care product or a medicine aiming at preventing and treating the glomerular disease. The above health care product and the medicine can be used for the diseases relevant to the chronic glomerular lesion, such as diabetes and metabolic syndrome and the like, so that the glomerular progressive course in the relevant diseases can be delayed and improved.

The present disclosure provides a method for treating and / or preventing nephrotic syndrome, such as but not limited to MCD and MN, and conditions related to nephrotic syndrome, such as but not limited to, proteinuria and edema, as well as diabetic nephropathy, diabetes mellitus, lupus nephritis or primary glomerular disease. The present disclosure further provides methods for reducing proteinuria and other disease states as discussed herein. Such methods comprise the therapeutic delivery of an Angptl4 polypeptide or Angptl4 polypeptide derivative to a subject.

The invention relates to a pure traditional Chinese medicine preparation for treating glomerular diseases. The pure traditional Chinese medicine preparation is prepared from the following raw materials in parts by weight: 30 parts of membranous milkvetch root, 12 parts of amur corktree bark, 15 parts of rhubarb, 40 parts of glabrous greenbrier rhizome, 20 parts of radix salviae miltiorrhizae, 15 parts of oriental waterplantain rhizome, 20 parts of epimedium herb, 15 parts of lalang grass rhizome and 30 parts of motherwort herb, and prepared by decoction, filtration, concentration of filtrate and drying. The pure traditional Chinese medicine preparation has significant efficacy for kidney diseases comprising acute and chronic glomerulonephritis, nephrotic syndrome, hypertensive nephropathy, diabetic nephropathy and early renal insufficiency caused by various reasons; furthermore, the raw materials are easily available, the production process is simple, the toxicity and side effects are small, and the administration is convenient, thereby providing the effective pure traditional Chinese medicine preparation for treating the kidney diseases.

The invention belongs to the technical field of medicine, and discloses a medicine for curing a chronic primary glomerular disease and a preparation method thereof. The medicine for curing the chronicprimary glomerular disease is prepared from the materials by weight: 30g of radix astragali seu hedysari, 10g of radix stephaniae tetrandrae, 12g of stir-fried with branrhizoma atractylodis macrocephalae, 15g of herba violae, 10g of bombyx batryticatus, 10g of plantaginis seed, 10g of poria cocos, 12g of fructus rubi and 6g of honey-fried radix glycyrrhizae. The medicine is subjected to rough extraction and is processed into a granule formulation shape. According to the medicine for curing the chronic primary glomerular disease and the preparation method thereof, the formulation is pure traditional Chinese medicine, and the medicine is safe and has no side-effect; the medicine has the efficacy of strengthening a spleen,tonifying a kidney, invigorating qi, consolidating superficies, dispelling pathogenicwind and eliminating dampness, mainly cures the chronic primary glomerular disease, and particularly cures a patient with symptoms of qi deficiency and edema; a chronic kidney disease patient is suitable to take the medicine for a long-term; the clinical oral doses are few, the curative effect is significant, the medicine can effectively facilitate regression of the edema, improve the clinical symptoms, and postpone the disease progression of the chronic primary glomerular disease; and a ranged of applying public is wide, and the medicine can produce social effects well and bring economic effects for the society.

The invention provides a heterocyclic compound containing piperidine as shown in a formula (I). The compounds are used for treating diseases and diseases related to complement alternative pathway activation, such as paroxysmal nocturnal hemoglobinuria (PNH), IgA nephropathy (IgAN) including C3 glomerulopathy (C3G), membranous nephropathy (MN) and other glomerular diseases, atypical hemolytic uremic syndrome (aHUS), age-related macular degeneration (AMD), diabetic retinopathy (DR), and other diseases associated with abnormal activation of the alternative complement pathway by inhibiting / regulating a complement factor B.

The present invention describes a non-invasive method to isolate with high efficiency, purity and reproducibility the population of renal progenitors CD133+CD24+, from urine samples of patients suffering from various glomerular diseases. Said renal progenitors can then easily be induced to differentiate into podocytes. The isolation of renal progenitors with the method of the invention allows the use of said cells as a cellular model of a disease for the in vitro study of genetic excluding exfoliated epithelial cells and blood cells mutations due to the podocyte or for the study of renal toxicity induced by potentially nephrotoxic drugs on the tubules.

Provided is a pharmaceutical composition useful for the prevention or therapy of glomerular diseases, in particular progressive chronic glomerular diseases. A preventive or therapeutic agent for a glomerular disease containing pyridoxamine or a salt thereof, and an angiotensin II receptor antagonist.

A targeting nanoparticle composition and method of treatment for diseases associated with major basement membrane components of blood vessels accessible from blood stream is presented. The composition includes pegylated perfluorocarbon nanoparticles having a targeting ligand attached that targets the basement membrane components, specifically collagen IV. The targeted nanoparticles may contain at least one pharmaceutically active agent capable of treating a glomerular disease such as lupus nephritis.

The present invention relates to a method for screening a compound for preventing, ameliorating or treating glomerular lesions or disease of kidney, characterized by assaying the regulating activity of compound on 4F2hc expression shown by contacting human peripheral blood mononuclear cells or monocytes or an established line of human cultured cells having a nature of human macrophages with macrophage-activating substances. The screening method is useful for screening compounds capable of preventing, ameliorating or treating glomerular lesions or disease of kidney.

The present invention provides an agent having a suppressive action against kidney glomerular disease and renal arteriosclerosis, a prophylactic agent for renal failure containing the above described agent, and functional foods expected to have a prophylactic effect for renal failure. The agent for preventing kidney glomerular disease and renal arteriosclerosis comprises Xaa Pro Pro as an active ingredient.

The following disclosure generally relates to methods of culturing podocytes in vitro. The cultures can be used for drug screening (such as medium or high throughput drug screening), and for studying molecular pathways involved in glomerular diseases. The disclosure also provides methods for analyzing the healthiness of podocytes in a cell culture. The disclosure also relates to diagnosis of kidney diseases.

The invention relates to methods, compositions, and kits for the treatment of proteinuria and / or hypertension (e.g., proteinuria and / or hypertension arising from primary renal disease (e.g., focal segmental glomerulosclerosis, glomerular disease) or secondary to other conditions (e.g., diabetes, diabetic nephropathy, liver disease). Specifically, the invention relates to methods involving combination therapy wherein an indoline (e.g., indapamide) is administered in combination with an anti-aldosterone agent (e.g., spironolactone and / or epleronone).

The present disclosure provides a method for treating and / or preventing nephrotic syndrome, such as but not limited to minimal change disease and membranous nephropathy, and conditions related to nephrotic syndrome, such as but not limited to, proteinuria and edema, as well as diabetic nephropathy, diabetes mellitus, lupus nephritis or primary glomerular disease. The present disclosure further provides methods for reducing proteinuria and other disease states as discussed herein. Such methods comprise the therapeutic delivery of an Angptl4 polypeptide or Angptl4 polypeptide derivative to a subject.

The present invention relates to a preventive and / or therapeutic agent for a glomerular disease containing, as active ingredients pitavastatin or a salt thereof and candesartan cilexetil or a salt thereof. The agent of the present invention exhibits an excellent effect in the prevention and / or therapy of a glomerular disease.

The following disclosure generally relates to methods of culturing podocytes in vitro. The cultures can be used for drug screening (such as medium or high throughput drug screening), and for studying molecular pathways involved in glomerular diseases. The disclosure also provides methods for analyzing the healthiness of podocytes in a cell culture. The disclosure also relates to diagnosis of kidney diseases.

The present disclosure provides a method for treating and / or preventing nephrotic syndrome, such as but not limited to MCD and MN, and conditions related to nephrotic syndrome, such as but not limited to, proteinuria and edema, as well as diabetic nephropathy, diabetes mellitus, lupus nephritis or primary glomerular disease. The present disclosure further provides methods for reducing proteinuria and other disease states as discussed herein. Such methods comprise the therapeutic delivery of an Angptl4 polypeptide or Angptl4 polypeptide derivative to a subject.

The present disclosure provides a method for treating and / or preventing a condition characterized as a nephrotic syndrome, such as but not limited to minimal change disease (MCD) and membranous nephropathy (MN), and conditions related to nephrotic syndrome, such as but not limited to, proteinuria and edema, as well as diabetic nephropathy, diabetes mellitus, lupus nephritis or primary glomerular disease. The present disclosure further provides methods for reducing proteinuria and other disease states as discussed herein. Such methods comprise the therapeutic delivery of an Angptl4 polypeptide or Angptl4 polypeptide derivative to a subject.

The present disclosure provides a method for treating and / or preventing nephrotic syndrome, such as but not limited to minimal change disease and membranous nephropathy, and conditions related to nephrotic syndrome, such as but not limited to, proteinuria and edema, as well as diabetic nephropathy, diabetes mellitus, lupus nephritis or primary glomerular disease. The present disclosure further provides methods for reducing proteinuria and other disease states as discussed herein. Such methods comprise the therapeutic delivery of an Angptl4 polypeptide or Angptl4 polypeptide derivative to a subject.